Introduction: Intrahepatic cholestasis of pregnancy is characterised by pruritus and elevated serum bile acids. The pruritus can be severe, and pharmacological options achieve inconsistent symptomatic improvement. Raised bile acids are linearly associated with adverse fetal outcomes, with existing management of limited benefit. We hypothesised that therapeutic plasma exchange removes pruritogens and lowers total bile acid concentrations, and improves symptoms and biochemical abnormalities in severe cases that have not responded to other treatments. Methods: Four women with severe pruritus and hypercholanemia were managed with therapeutic plasma exchange. Serial blood biochemistry and visual analogue scores of itch severity were obtained. Blood and waste plasma samples were collected before and after exchange; individual bile acids and sulfated progesterone metabolites were measured with HPLC-MS, autotaxin activity and cytokine profiles with enzymatic methods. Results were analysed using segmental linear regression to describe longitudinal trends, and ratio t tests. Results: Total bile acids and visual analogue itch scores demonstrated trends to transiently improve following plasma exchange, with temporary symptomatic benefit reported. Individual bile acids (excluding the drug ursodeoxycholic acid), and the sulfated metabolites of progesterone reduced following exchange (P = .03 and P = .04, respectively), whilst analysis of waste plasma demonstrated removal of autotaxin and cytokines. Conclusions: Therapeutic plasma exchange can lower potentially harmful bile acids and improve itch, likely secondary to the demonstrated removal of pruritogens. However, the limited current experience and potential complications, along with minimal sustained symptomatic benefit, restrict its current use to women with the most severe disease for whom other treatment options have been exhausted.
1 | INTRODUCTION
| Intrahepatic cholestasis of pregnancy
Intrahepatic cholestasis of pregnancy (ICP) affects 0.7% UK pregnant women; with ethnic and geographic variation. It is diagnosed by elevated serum bile acids in the presence of an itch not attributable to another disorder and can be associated with other markers of liver dysfunction (elevated transaminases, steatorrhea and impaired coagulation). Notably, maternal disease is associated with increased maternal dyslipidemia, gestational diabetes mellitus and pre-eclampsia. The elevations in serum bile acid concentration have been linearly linked to increased adverse perinatal outcomes (spontaneous preterm birth, meconium staining of the amniotic fluid, fetal asphyxia and stillbirth), with the odds of each event increasing by 1-2% per μmol/L increase in serum bile acids above 40 μmol/L. 1 These findings were confirmed in a prospective UK cohort study. 2 The mainstay of treatment for ICP is typically with ursodeoxycholic acid (UDCA), which is associated with mild improvements in pruritus, 3 serum bile acids and alanine aminotransferase. 4, 5 However, UDCA rarely normalises these parameters, particularly for women with severe disease (BA ≥40 μmol/L). Additional treatment with rifampicin can improve serum bile acids in >50% of women with ICP and improves itch in patients with primary biliary cholangitis. 6, 7 Further treatment options for severely affected women have been limited, secondary to concerns of safety in pregnancy and paucity of potential drug candidates.
| Pruritus in ICP
The cause of pruritus in ICP has not been clearly established, although a number of molecules have been proposed as pruritogens. Bile acids themselves cause itch when applied to the skin, 8 and the secondary bile acid deoxycholic acid was shown to cause itch in a murine model. 9 However, their serum concentrations do not correlate well with severity of itch. 10, 11 Lysophosphatidic acid (LPA) is a potent pruritogen, produced from lysophosphatidylcholine by the enzyme autotaxin, whose levels are markedly elevated in ICP. 12 The sulfated metabolites of progesterone are also elevated in the serum of women with ICP, and the metabolite 5β-pregnan-3α,20α-diolsulfate (PM3S) was significantly associated with itch severity in ICP, 10 and can signal via TGR5 to cause itch.
Progesterone sulfates also play a role in the etiology of ICP. They are elevated in maternal serum, and have been shown to function as partial agonists of the nuclear bile acid receptor farnesoid X receptor (FXR). 13 Progesterone sulfates can also competitively inhibit canalicular transport proteins that mediate influx and efflux of bile acids. 14, 15 The drug UDCA causes reduced serum and urine concentrations of progesterone sulfates, 10,16 a likely explanation for improved maternal serum bile acids and pruritus in treated women.
ICP has been associated with elevations in serum inflammatory cytokines, 17 particularly with more severe disease.
Additionally, altered cytokine levels have been associated with pruritus, notably interleukin 2 (Il-2), which elicits a marked itch response when injected intradermally. 18 1.3 | Therapeutic plasma exchange in ICP Therapeutic plasma exchange (TPE) is the extracorporeal separation of blood components, removal and replacement of plasma alongside existing blood constituents. Its use in pregnancy has been limited to conditions typically associated with immunoglobulin-related disease, dramatically elevated lipids, and severely deranged coagulation. TPE has been used for pruritus associated with primary biliary cholangitis, with improvement in the majority of the 37 reported cases, 2 of whom were pregnant, 19 and for a patient with pregnancy-related pruritus secondary to progressive familial intrahepatic cholestasis (PFIC) with moderate success, as the patient subsequently required molecular adsorbent recirculating system (MARS) therapy. 20 Four case reports of TPE use for ICP were identified, which report varying success. [21] [22] [23] [24] Thus, it presents a novel therapeutic option for women with severe ICP, with the aims of improving their debilitating pruritus and reducing serum bile acid concentrations (and therefore adverse perinatal outcomes). We hypothesised that TPE could lower total bile acids and improve itch severity by the removal of circulating pruritogens, and evaluated samples from women who received TPE for ICP. 
| MATERIALS AND METHODS

| Patient details
| Symptomatic and biochemical measurements
Participants completed serial visual analogue scores of itch severity (0-100) and their clinical blood test results were recorded. In addition, three women donated blood samples before and after exchanges and prior to delivery, with waste plasma being collected for two of the women during the exchange. Individual bile acids and the sulfated progesterone metabolites 5α-pregnan-3α,-20α-diol-3,20-disulfate (PM2DiS), PM3S, 5α-pregnan-3α-S, 20-one (PM4S) and 5α-pregnan-3β-S, 20-one (PM5S) were measured by high-performance liquid chromatography-mass spectrometry, and autotaxin activity by a fluorimetric assay in which the liberation of choline from lysophophatidylcholine was measured, as previously described. 10, 13 Cytokines were assessed by electrochemiluminescence using the U-PLEX Proinflammatory Panel 1 Human Kit (Meso Scale Diagnostics, MA, USA) according to manufacturer instructions.
| Statistics
Serial itch scores, serum total bile acid concentrations and alanine aminotransferase (ALT) levels were plotted for each patient, and segmental linear regression performed before and after the first exchange individually. Pruritogens were compared from before and after TPE using ratio t tests, with significance determined at P < .05. Analyses were performed using GraphPad Prism 7.03 (GraphPad Software, USA).
3 | RESULTS
| Clinical histories
The four participants were multiparous, with previous pregnancies complicated by ICP ( Table 1) . As all the women were still at relatively early gestational weeks, such that iatrogenic preterm delivery would be a serious risk to the fetus, all other treatment options exhausted and the associated itch judged a risk to the maternal health, the women underwent treatment with TPE. Exchanges were performed as in-patients or day-patients within intensive care, high dependency or renal specialist units. Vascular access was via central venous catheter or implanted port. TPE was well-tolerated, and all women reported periods of subjective benefit to pruritus, including longer sleep and tolerance of clothing/ sheets, but the duration and extent of this improvement varied. The overall trends of serum total bile acid and ALT concentrations reduced after the first exchange, although total bile acids returned to pre-exchange levels for the patient who underwent only 3 exchanges (Figure 1 ). 
| Effect of TPE on bile acids and pruritogens
Individual serum bile acids were measured in samples from 3 women. Total bile acids, excluding the pharmacological bile acid UDCA, reduced after TPE (Figure 2A) , with taurine-conjugated bile acids demonstrating the most sizeable fall with TPE (Supporting Information Figure S1 ). Cholic acid is the bile acid species that particularly increases in ICP, 25 and it showed the largest magnitude of trend to reduce following TPE, with minimal increase prior to delivery (Supporting Information Figure S1 ). There was a nonsignificant trend for autotaxin activity to fall following TPE (P = .05, Figure 2B ), and the combined total of four progesterone sulfates measured was significantly lower following TPE (P = .04, Figure 2C ), although all tended to increase prior to delivery, consistent with gestational increases previously identified (Supporting Information Figure S2A ). Serum cytokines from both pro-and anti-inflammatory groups showed nonsignificant reductions following TPE, and there was interindividual variability between the effects of TPE across the course of treatment and prior to delivery ( Figure 2D and Supporting Information Figure 2B) . Analysis of the waste plasma confirmed that bile acids were removed by TPE at relatively consistent concentrations throughout the period of plasmapheresis (following 1.5 and 3 L exchange for one woman, and 2 and 4 L for the other, with 420 and 288 mg bile acids removed per exchange, respectively, Table 2 ). Similarly, progesterone sulfates, cytokines and autotaxin activity were detected in waste plasma at similar, if slightly lower, concentrations to blood levels postexchange (Supporting Information Figure S3 ), and their values fell only slightly throughout the period of TPE.
| DISCUSSION
This case series has demonstrated that TPE can improve symptoms and reduce maternal serum bile acid and aminotranferase concentrations. The mechanism by which this occurs includes removal of putative pruritogens, including progesterone sulfates and autotaxin. Whilst symptomatic benefits were transient, some biochemical improvements, particularly for non-UDCA bile acid concentrations and autotaxin activity, appeared to be long-lasting. These are likely to be of benefit to fetal health, and it is encouraging that the four ICP pregnancies treated with TPE in this series resulted in the birth of healthy neonates. 
| Strengths and limitations
Investigating the use of uncommon treatments in rare disorders, particularly during pregnancy, can be challenging, and the clinician is often required to perform procedures speculatively. A strength of our study is the detailed observational data obtained in combination with mechanistic investigations using blood and plasma samples. As TPE is an invasive procedure performed on women with the most severe disease, management was personalised, and therefore different treatment regimens were used for each case. This resulted in inconsistent sample collection across cases which limited the interpretation of the biochemical analyses. Similarly, the small number of women limited our ability to achieve statistical significance for some comparisons. Finally, the experience of pruritus is subjective; we used visual analogue scoring as a validated P r e -e x c h a n g e P o s t -e x c h a Pre-exchange Post-exchange
The effect of therapeutic plasma exchange on bile acids, sulfated progesterone metabolites, autotaxin activity and cytokines. Box-whisker plots show median and boxes show interquartile range, with whiskers demonstrating range for results of blood analyses taken immediately before (dark boxes) and after (light boxes) therapeutic plasma exchange for three women, for 1 (patient 1) or two exchanges (patients 3, 4). Results were compared using ratio t tests, with P < .05 indicated as significant (*). A, The sum of serum bile acids individually measured by HPLC-MS excluding ursodeoxycholic acid (UDCA); B, autotaxin activity; C, the sum of the sulfated progesterone metabolites 5α-pregnan-3α,-20α-diol-3,20-disulfate (PM2DiS), 5β-pregnan-3α-20α-diol-sulfate (PM3S), 5αpregnan-3α-S, 20-one (PM4S) and 5α-pregnan-3β-S, 20-one (PM5S); D, the sum of individually-measured cytokines in pro-and anti-inflammatory groups. Pro-inflammatory cytokines measured: IFNγ, IL-1β, IL-6, IL-8, IL12p70 and TNFα; anti-inflammatory cytokines: Il-2, Il-4, Il-10 and Il-13 Results show mean pruritogens lost in aliquots of waste plasma at the same point in exchange for two cycles of therapeutic plasma exchange. assessment of pruritus severity, yet the possibility exists of a placebo effect for TPE to improve pruritus.
| Effect of TPE on bile acids and pruritogens
Of the three women who provided blood samples for mechanistic studies, two were treated with the drug UDCA which enhances choleresis and reduces apoptosis. UDCA further enhances placental bile acid transport, thereby enhancing fetal bile acid excretion. 26 Thus, the increased proportion of UDCA in the bile acid pool following TPE is likely to be of fetalmaternal benefit. Progesterone sulfates are removed by TPE, and this corresponded with a subjective improvement in pruritus. However, the reduced pruritus did not persist, and the increase in progesterone sulfates in samples taken prior to delivery reflects the fact that they increase towards term in ICP pregnancies. 10 As progesterone sulfates are partial agonists of FXR, 13 their removal may also explain the reduction of serum bile acids following TPE. Consistent with this, it is noteworthy that all cases had improved ALT concentrations after TPE, and three of the four cases had a reduction in serum bile acids, although none returned to normal. Particularly as total bile acids experience diurnal variation, with peak bile acids postprandially, 27 the reduction in the overall trend of bile acid concentrations during plasma exchanges is reassuring. A therapeutic option for women with rapidly deteriorating liver function is delivery of the fetus as this is likely to result in resolution of maternal hepatic impairment, but this is associated with increased risks of neonatal morbidity and mortality, and subsequent cognitive impairment. 28, 29 The use of TPE to treat women who do not respond to other treatments for cholestasis may therefore improve maternal liver function as well as symptoms to enable prolongation of pregnancy. As the course of ICP in subsequent pregnancies is not consistent (demonstrated by patient 3, for whom gestations of birth varied between 29 and 39 gestational weeks for her previous 6 pregnancies), we cannot use this case series to conclude this benefit of TPE, however that none of the women experienced spontaneous preterm birth as a complication of their ICP is encouraging. The removal of autotaxin into waste plasma with TPE is consistent with its reduced serum activity, and improved itch severity, postexchange. The prolonged reduction in serum autotaxin activity is striking as it has been shown that autotaxin is very rapidly cleared from the blood (the half-life in blood of mice is about 10 min, and this is likely to also be the case in humans). 30, 31 Hence, this would infer that TPE causes a relatively sustained reduction in the serum factor(s) that induce autotaxin expression and secretion into the blood. The production of autotaxin is stimulated by inflammatory cytokines, which in turn are increased by LPA, the enzymatic product of autotaxin, 32, 33 hence the likely combined benefit of the cytokine reductions seen with TPE. Given the association of preterm labour with ICP, reducing inflammatory cytokines that have independently been associated with premature labour (eg, Il-6, Il-10 and TNFα) may be an additional benefit of TPE in ICP. 34 However, TPE is not selective, and we also demonstrated the removal of anti-inflammatory cytokines into waste plasma, which could temper this benefit.
| CONCLUSIONS
TPE provides an alternative treatment option for women with severe ICP that leads to a short-lasting improvement in pruritus (with concurrent reduction of circulating pruritogens), and trends to reduce serum bile acid and cytokine concentrations that may improve maternal disease and be of benefit to the fetus. For women with severe biochemical derangements, TPE may result in sufficient improvement in hepatic function to enable prolongation of pregnancy. However, it remains a treatment of last resort due to its invasiveness and short-lasting benefits.
